This eye toxicity limits long-term use of the drugs. The risk of toxicity is low for individuals without complicating conditions during the first 5 years of treatment using less than 6.5 mg/kg/day of hydroxychloroquine or 3 mg/kg/day of chloroquine, and/or cumulative doses of less than 1000 gram and 460 gram (total dose), respectively. Chloroquine diphosphate Hydroxychloroquine and skin darkening Plaquenil patient assistance program Eye care specialists provide a valuable service when screening for Plaquenil retinal toxicity and advising the treating physician or rheumatologist with regards to the patient’s risk, safe dosing and appropriate screening procedures. With the updates of the new guidelines regarding screening for Plaquenil-related retinal toxicity, we must be. Risk factors for retinopathy included higher doses and longer durations of use. Other major factors are concomitant renal disease, use of tamoxifen and prior retinal or macular disease. Thus, the new AAO screening and follow-up recommendations are shown below. Screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 92 2011;1182415-22. 93 5. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of O. 94 Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy 2016 95 Revision. Ophthalmology. 2016. 96 6. The earliest signs of toxicity include bilateral paracentral visual field changes (best detected with a red test object) and a subtle granular depigmentation of the paracentral RPE. Some physicians suggest that lean body weight is more accurate when calculating daily dosage. Chloroquine retinal screening Retinal Physician - Hydroxychloroquine Maculopathy An., My Take on New Ocular Screening Guidelines for Plaquenil. Plaquenil 300 mgDrug interactions between hydroxychloroquine and xanaxPlaquenil sore throat Screening for hydroxychloroquine retinopathy The aim of screening is not to prevent retinopathy but to detect the earliest definitive signs of it before a patient notices any symptoms, because of this you have been invited to take part in the screening programme at the Eye Treatment centre. Where will the screening take place? Hydroxychloroquine screening. AMERICAN COLLEGE OF RHEUMATOLOGY. Eye screening for patients taking hydroxychloroquine.. In 2016, with new scientific data, the American Academy of Ophthalmology revised their screening recommendations for patients on chloroquine for longer than 1 year 5. The two most important risk factors for retinopathy are the duration of chloroquine treatment and a daily dose of chloroquine 2.3 mg/kg of the patient's actual body weight. Chloroquine is a potent drug used for the treatment of various diseases, including malaria and a range of connective tissue disorders. Chloroquine retinopathy is an important complication that may appear even years after cessation of the drug, presenting with impaired visual acuity, central vision loss and progressive damage that could result in irreversible blindness. Since the initial screening and monitoring recommendations were published in 2002, there have been reports of retinal toxicity associated with the use of Plaquenil. Furthermore, the advent of novice sensitive diagnostic modalities has led to a revision of the recommended guidelines for patients using Plaquenil see “2011 Plaquenil Screening.